Hepatocellular carcinoma treated with transarterial
chemoembolization in cirrhotic and non-cirrhotic liver
retrospective analysis

k 2020

Hepatocellular carcinoma treated with transarterial chemoembolization in cirrhotic and non-cirrhotic liver retrospective analysis

ROHAN, Tomáš, Michal UHER, Peter MATKULČÍK, Jan ZAVADIL, Vlastimil VÁLEK et. al.

Základní údaje

Originální název

Hepatocellular carcinoma treated with transarterial chemoembolization in cirrhotic and non-cirrhotic liver retrospective analysis

Autoři

ROHAN, Tomáš (203 Česká republika, garant, domácí), Michal UHER (203 Česká republika, domácí), Peter MATKULČÍK (703 Slovensko, domácí), Jan ZAVADIL (203 Česká republika, domácí), Vlastimil VÁLEK (203 Česká republika, domácí) a Tomáš ANDRAŠINA (703 Slovensko, domácí)

Vydání

ECIO 2020, 2020

Další údaje

Jazyk

angličtina

Typ výsledku

Prezentace na konferencích

Obor

30224 Radiology, nuclear medicine and medical imaging

Stát vydavatele

Francie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Kód RIV

RIV/00216224:14110/20:00116825

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

hepatocellular carcinoma; transarterial chemoembolization; survival analysis

Štítky

rivok

Příznaky

Mezinárodní význam

Změněno: 5. 11. 2020 09:39, MUDr. Tomáš Rohan, Ph.D.

Anotace

V originále

Purpose To compare results of hepatocellular carcinoma treatment with transarterial chemoembolization and identify prognostic factors affecting survival. Material and methods Retrospective analysis of patients with HCC treated with TACE in tertially referal hospital in 2005-2018. Based on the presence of the chronic liver disease were patient divided in two groups (with and without chronic liver disease). In each group were on CT/MRI before initial TACE evaluated and statistically analysed (survival log rank test, uni and multivariate analysis) dedicated prognostic factors (one or more lesion, size of the biggest lesion, uni or bilobar disease, portal vein trombosis). Results In the analysis were included 122 patients (18% females, avg 66 years) with known chronic liver disease and 35 patients (16.7% females, avg. 66 years) without known liver disease. Although the biggest lesion was significantly bigger in patients without chronic liver disease (median 11.0 vs 6.0 cm, p=0,001), the survival rate from 1.TACE was higher in this group (median 35.3 vs 20.0 months, p=0,078), any other evaluated risk factors except the presence of chronic liver disease were significantly different. The most important survival risk factor except the chronic liver disease was in both groups the size of the lesion (HR 1.264/cm vs 1.125/cm) and bilobar involvement (HR 5.576 vs 2.257), in addition, in chronic liver disease also portal vein thrombosis (HR 3.279). Conclusion Better survival rate was observed in HCC in liver without chronic disease, although the lesions were significantly larger. The most important risk factor in this group was bilobar involvement and the size of the biggest lesion.

Návaznosti

MUNI/A/1488/2019, interní kód MU

Název: Význam radiologických intervencí a pokročilých zobrazovacích metod v diagnostice a léčbě onkologických pacientů

Investor: Masarykova univerzita, Význam radiologických intervencí a pokročilých zobrazovacích metod v diagnostice a léčbě onkologických pacientů, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

Citovat

ROHAN, Tomáš, Michal UHER, Peter MATKULČÍK, Jan ZAVADIL, Vlastimil VÁLEK a Tomáš ANDRAŠINA. Hepatocellular carcinoma treated with transarterial chemoembolization in cirrhotic and non-cirrhotic liver retrospective analysis. In ECIO 2020. 2020.

@proceedings{1689038,
   author = {Rohan, Tomáš and Uher, Michal and Matkulčík, Peter and Zavadil, Jan and Válek, Vlastimil and Andrašina, Tomáš},
   booktitle = {ECIO 2020},
   keywords = {hepatocellular carcinoma; transarterial chemoembolization; survival analysis},
   language = {eng},
   title = {Hepatocellular carcinoma treated with transarterial chemoembolization in cirrhotic and non-cirrhotic liver retrospective analysis},
   url = {https://library.cirse.org/eciovirtual/crs/hepatocellular-carcinoma-treated-with-transarterial-chemoembolisation-in-cirrhotic-and-non-cirrhotic-liver-retrospective-analysis},
   year = {2020}
}

TY  - CONF
ID  - 1689038
AU  - Rohan, Tomáš - Uher, Michal - Matkulčík, Peter - Zavadil, Jan - Válek, Vlastimil - Andrašina, Tomáš
PY  - 2020
TI  - Hepatocellular carcinoma treated with transarterial chemoembolization in cirrhotic and non-cirrhotic liver retrospective analysis
KW  - hepatocellular carcinoma
KW  - transarterial chemoembolization
KW  - survival analysis
UR  - https://library.cirse.org/eciovirtual/crs/hepatocellular-carcinoma-treated-with-transarterial-chemoembolisation-in-cirrhotic-and-non-cirrhotic-liver-retrospective-analysis
N2  - Purpose To compare results of hepatocellular carcinoma treatment with transarterial chemoembolization and identify prognostic factors affecting survival. Material and methods Retrospective analysis of patients with HCC treated with TACE in tertially referal hospital in 2005-2018. Based on the presence of the chronic liver disease were patient divided in two groups (with and without chronic liver disease). In each group were on CT/MRI before initial TACE evaluated and statistically analysed (survival log rank test, uni and multivariate analysis) dedicated prognostic factors (one or more lesion, size of the biggest lesion, uni or bilobar disease, portal vein trombosis). Results In the analysis were included 122 patients (18% females, avg 66 years) with known chronic liver disease and 35 patients (16.7% females, avg. 66 years) without known liver disease. Although the biggest lesion was significantly bigger in patients without chronic liver disease (median 11.0 vs 6.0 cm, p=0,001), the survival rate from 1.TACE was higher in this group (median 35.3 vs 20.0 months, p=0,078), any other evaluated risk factors except the presence of chronic liver disease were significantly different. The most important survival risk factor except the chronic liver disease was in both groups the size of the lesion (HR 1.264/cm vs 1.125/cm) and bilobar involvement (HR 5.576 vs 2.257), in addition, in chronic liver disease also portal vein thrombosis (HR 3.279). Conclusion Better survival rate was observed in HCC in liver without chronic disease, although the lesions were significantly larger. The most important risk factor in this group was bilobar involvement and the size of the biggest lesion.
ER  -

Podrobný výpis o publikaci